Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer
Copyright policy )Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer
We investigated the efficacy of maintenance hormone therapy (MHT), which was given to hormone positive metastatic breast cancer (MBC) patients in non-progression status to the previous chemotherapy.This study retrospectively analyzed 76 MBC patients who had been treated with MHT from 2006 to 2010 at a single institute.For the 76 patients reviewed, the median progression free survival (PFS) to MHT was 14.4 months (95% CI, 11.6-17.3). Prolonged PFS was associated with less previous palliative chemotherapy, fewer metastatic sites, and the absence of visceral metastasis in univariate analysis. Multivariate analysis showed that only the number of previous palliative chemotherapy (HR 1.73, 95% CI, 1.00-2.98; P = 0.04) remained as a significant variable. MHT was generally well tolerated.MHT showed considerable efficacy and tolerability in this study. Further randomized prospective study is warranted.
- Yonsei University Medical Library Korea (Republic of)
- Yonsei University Korea (Republic of)
- Yonsei University Health System Korea (Republic of)
Breast Neoplasms/pathology, Kaplan-Meier Estimate, PR, progesterone receptor, PFS, Palliative Care*, Breast cancer, MHT, Receptors, Progesterone/analysis, Neoplasm Metastasis, progression free survival, Antineoplastic Agents/therapeutic use*, Aromatase Inhibitors, Palliative Care, Aromatase Inhibitors/therapeutic use*, Selective Estrogen Receptor Modulators/adverse effects, Selective Estrogen Receptor Modulators/therapeutic use*, OS, Middle Aged, Receptors, Estrogen, Estrogen/analysis, Breast Neoplasms/drug therapy*, Female, metastatic breast cancer, Receptors, Progesterone, estrogen receptor, Adult, Selective Estrogen Receptor Modulators, MBC, Maintenance, overall survival, 610, Antineoplastic Agents, Breast Neoplasms, Disease-Free Survival, Maintenance Chemotherapy, medroxyprogesteron acetate, Humans, Hormone therapy, Aged, Retrospective Studies, maintenance hormone therapy, response evaluation criteria in solid tumors, Maintenance Chemotherapy*, Antineoplastic Agents/adverse effects, Breast Neoplasms/chemistry, MPA, ER, RECIST, Aromatase Inhibitors/adverse effects
Breast Neoplasms/pathology, Kaplan-Meier Estimate, PR, progesterone receptor, PFS, Palliative Care*, Breast cancer, MHT, Receptors, Progesterone/analysis, Neoplasm Metastasis, progression free survival, Antineoplastic Agents/therapeutic use*, Aromatase Inhibitors, Palliative Care, Aromatase Inhibitors/therapeutic use*, Selective Estrogen Receptor Modulators/adverse effects, Selective Estrogen Receptor Modulators/therapeutic use*, OS, Middle Aged, Receptors, Estrogen, Estrogen/analysis, Breast Neoplasms/drug therapy*, Female, metastatic breast cancer, Receptors, Progesterone, estrogen receptor, Adult, Selective Estrogen Receptor Modulators, MBC, Maintenance, overall survival, 610, Antineoplastic Agents, Breast Neoplasms, Disease-Free Survival, Maintenance Chemotherapy, medroxyprogesteron acetate, Humans, Hormone therapy, Aged, Retrospective Studies, maintenance hormone therapy, response evaluation criteria in solid tumors, Maintenance Chemotherapy*, Antineoplastic Agents/adverse effects, Breast Neoplasms/chemistry, MPA, ER, RECIST, Aromatase Inhibitors/adverse effects
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).6 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!